| abstract |
The present invention addresses the problem of providing: a method for identifying patients having malignant tumors and more likely to benefit from the effects of immune checkpoint inhibitors; and an agent that is for inhibiting the progress and recurrence of malignant tumors, and/or treating malignant tumors, and that is characterized by being prescribed on the basis of the method.　The present invention provides an agent that is for inhibiting the progress and recurrence of malignant tumors, and/or treating malignant tumors, and that is characterized by: involving identification of patients having malignant tumors and more likely to benefit from immune checkpoint inhibitors, by use of a plurality of combinations of two sets of assessment items and specific conditions specified by the respective two-set combinations; and being prescribed on the basis of the identification. |